New cancer drug combo enters human testing

NCT ID NCT05007782

Recruiting now Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called denikitug, alone or with another drug (zimberelimab), in 416 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drugs shrink tumors. It is a first-in-human study, so results are very preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Denikitug (GS-1811) and zimberelimab

What this could lead to

If successful, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.

What could go wrong

This is an early phase 1 trial focused on safety and dosing, not yet on effectiveness. Many experimental cancer drugs fail in early testing, and side effects are unknown.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States
Chang Gung Medical Foundation Linkou Chang Gung Memorial Hospital
RECRUITING

Taoyuan City, 33308, Taiwan
Changhua Christian Hospital
RECRUITING

Changhua, 500, Taiwan
Chi Mei Hospital, Liouying
RECRUITING

Tainan, 73657, Taiwan
Chris O'Brien Lifehouse
RECRUITING

Camperdown, New South Wales, 2050, Australia
Clinica Universidad de Navarra
RECRUITING

Pamplona, 31008, Spain
Hospital Universitari Vall d´Hebrón
RECRUITING

Barcelona, 08035, Spain
Hospital Universitario 12 de Octubre
RECRUITING

Madrid, 28041, Spain
Hospital Universitario Quironsalud Madrid
RECRUITING

Madrid, 28223, Spain
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
MD Anderson Cancer Center
RECRUITING

Madrid, 28033, Spain
Monash Medical Centre
RECRUITING

Clayton, Victoria, 3168, Australia
NEXT Oncology
RECRUITING

San Antonio, Texas, 78229, United States
National Taiwan University Cancer Center (NTUCC)
RECRUITING

Taipei, 100229, Taiwan
National Taiwan University Hospital
RECRUITING

Taipei, 100, Taiwan
Peter MacCallum Cancer Centre
RECRUITING

Melbourne, Victoria, 3000, Australia
Sarah Cannon Research Institute at Mary Crowley
RECRUITING

Dallas, Texas, 75230, United States
Smilow Cancer Center
COMPLETED

New Haven, Connecticut, 06510, United States
Stanford Cancer Center
RECRUITING

Palo Alto, California, 94305, United States
Taipei Tzu Chi General Hospital
WITHDRAWN

Taipei, 110, Taiwan
Taipei Veterans General Hospital
RECRUITING

Taipei, 11217, Taiwan
Tennessee Oncology, PLLC
RECRUITING

Nashville, Tennessee, 37203, United States
University Health Network, Princess Margaret Cancer Centre
RECRUITING

Toronto, M5G 2M9, Canada
University of California San Diego
RECRUITING

La Jolla, California, 92093, United States
University of Texas Southwestern Medical Center
RECRUITING

Dallas, Texas, 39090, United States
University of Wisconsin Clinical Sciences Center
RECRUITING

Madison, Wisconsin, 53705, United States